ArticleThe Lancet. Microbe2022

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.

Jin Young Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.